Milestone demonstrates the growing customer adoption of the Company’s proprietary technologyLEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in ...

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping ...

So, a new and faster test for it is a great idea. Which is what T2 Biosystems now has: “T2 Biosystems (NASDAQ:TTOO) has received breakthrough device status from the US Food and Drug Administration for ...

T2 Biosystems inked an $8.5 million deal with Canon U.S. Life Sciences to develop a rapid diagnostic test for Lyme disease, expanding its offerings and looking to carve a niche in a growing market.